Using 298 urothelial cancer patient cohorts with PD-L1 blockade cancer immunotherapy with atezolizumab, we found significant upregulation of INFG expression between responders and non-responders (fold change = 2.3, Moderated T test P = 1.8e−05; Fig. 4F). The gene discussed is CD274; the disease is cancer.